Shopping Cart 0
Cart Subtotal
USD 0

Repligen Corp (RGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Repligen Corp (Repligen) is a bioprocessing life science company that develops and commercializes consumable products for manufacturing biological drugs. The company's products include Protein A affinity resins, Protein A ligands, ELISA kits, alternating tangential flow system, OPUS pre packed chromatography columns, and cell culture supplements. It manufactures Protein A, which is a critical reagent used to manufacture monoclonal antibody therapeutics. Repligen's products find application in upstream applications, downstream applications, process intensification, and continuous processing. It caters to biopharmaceutical companies and contract manufacturing organizations. The company operates through its manufacturing facilities located in Lund, Sweden; Ravensberg, Germany; and Shrewsbury and Rancho Dominguez, the US. Repligen is headquartered in Waltham, Massachusetts, the US.

Repligen Corp (RGEN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Repligen Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Repligen Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Repligen Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Repligen Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Repligen Corp, Medical Devices Deals, 2012 to YTD 2018 9

Repligen Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Repligen Corp, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Refine Technology Enters Into Technology Integration Agreement With Thermo Fisher Scientific 11

Refine Technology Enters Into Co-Development Agreement With Wuhan Institute of Biological Products 12

Sartorius Stedim Biotech Enters Into Co-Development With Refine Technology 13

Licensing Agreements 14

BioMarin Enters Into Licensing Agreement With Repligen For Histone Deacetylase Inhibitor Portfolio 14

Equity Offering 15

Repligen Raises USD120 million in Public Offering of Shares 15

Debt Offering 17

Repligen Raises USD115 Million in Public Offering of 2.125% Notes Due 2021 17

Asset Transactions 19

Innovate Biopharma Acquires Assets Related to RG-1068 from Repligen 19

Acquisition 20

Repligen Acquires TangenX Technology from Novasep Holding for USD39 Million 20

Repligen Acquires Atoll from UV-Cap 21

Repligen Acquires Refine Technology for USD35.4 Million 22

Repligen Corp-Key Competitors 23

Repligen Corp-Key Employees 24

Repligen Corp-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Aug 02, 2018: Repligen Reports Second Quarter 2018 Financial Results 26

May 08, 2018: Repligen Reports First Quarter 2018 Financial Results 28

Feb 22, 2018: Repligen Announces Fourth Quarter 2017 Financial Results 30

Nov 09, 2017: Repligen Reports Third Quarter 2017 Financial Results 33

Aug 03, 2017: Repligen Reports Second Quarter 2017 Financial Results 36

May 04, 2017: Repligen Reports First Quarter 2017 Financial Results 39

Feb 22, 2017: Repligen Reports Fourth Quarter 2016 Financial Results, Provides Guidance for 2017 41

Product News 43

Mar 20, 2018: Repligen Announces Market Launch of OPUS 80R, Reinforces Technology Leadership in Pre-Packed Chromatography 43

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44


List Of Figure

List of Figures

Repligen Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Repligen Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Repligen Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Repligen Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Repligen Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Repligen Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Repligen Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Repligen Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Repligen Corp, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Repligen Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Repligen Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Repligen Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Repligen Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Repligen Corp, Deals By Therapy Area, 2012 to YTD 2018 8

Repligen Corp, Medical Devices Deals, 2012 to YTD 2018 9

Repligen Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Refine Technology Enters Into Technology Integration Agreement With Thermo Fisher Scientific 11

Refine Technology Enters Into Co-Development Agreement With Wuhan Institute of Biological Products 12

Sartorius Stedim Biotech Enters Into Co-Development With Refine Technology 13

BioMarin Enters Into Licensing Agreement With Repligen For Histone Deacetylase Inhibitor Portfolio 14

Repligen Raises USD120 million in Public Offering of Shares 15

Repligen Raises USD115 Million in Public Offering of 2.125% Notes Due 2021 17

Innovate Biopharma Acquires Assets Related to RG-1068 from Repligen 19

Repligen Acquires TangenX Technology from Novasep Holding for USD39 Million 20

Repligen Acquires Atoll from UV-Cap 21

Repligen Acquires Refine Technology for USD35.4 Million 22

Repligen Corp, Key Competitors 23

Repligen Corp, Key Employees 24

Repligen Corp, Other Locations 25

Repligen Corp, Subsidiaries 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Repligen Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.